STTK | Shattuck Labs, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.45 - 3.75
52 Week Range	1.3300 - 11.76
Beta	1.22
Implied Volatility	449.56%
IV Rank	68.04%
Day's Volume	104,731
Average Volume	412,793
Shares Outstanding	47,727,300
Market Cap	167,045,550
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-10-09

Valuation
Profitability
Growth
Health
P/E Ratio	-1.91
Forward P/E Ratio	-0.98
EPS	-1.83
1YR Price Target	12.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	75
Country	USA
Website	STTK

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

STTK's peers: APLT, ARVN, BCAB, PMCB, CCCC, CDXS, CLGN, CLLS, CSBR, ELYM, FHTX, GBIO, GLUE, HCWB, IKNA, IMAB, IMUX, IOBT, IPA, IPHA, KYMR, KZR, LUMO, LYEL, MTNB, NRIX, PRLD, RLMD, SEER, SLN, PRDS, IPSC, PMVP, STOK, THTX, TNGX, TSHA, VINC, VOR, HLVX, MLEC, ZVRA, GRI

*Chart delayed

Analyzing fundamentals for STTK we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is passable. For more detailed analysis please see STTK Fundamentals page.

Watching at STTK technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on STTK Technicals page.